S. Poli-Bigelli, J. Rodrigues-Pereira, A. Carides
Jun 15, 2003
Citations
25
Influential Citations
564
Citations
Quality indicators
Journal
Cancer
Abstract
Aprepitant is a novel neurokinin 1 (NK1) antagonist that has been shown to improve control of chemotherapy‐induced nausea and vomiting (CINV) when added to a standard antiemetic regimen of a 5‐hydroxytriptamine‐3 antagonist plus a corticosteroid. The authors sought to evaluate further the efficacy and tolerability of aprepitant plus standard therapy in a large clinical trial.